About Eiko Lifesciences Limited
Data last updated: 06 February 2026
Eiko Lifesciences Limited is a public limited company based in Thane, Maharashtra, India. It specialises in specialty chemicals, a part of the broader chemicals and materials sector. Incorporated on 07 January 1977, the company has been in operation for over 49 years.
Registered with ROC Mumbai under CIN L65993MH1977PLC258134. Listed on BSE: 540204.
Capital: an authorised share capital of ₹20 Cr and a paid-up capital of ₹13.72 Cr. Formerly known as Ornate Ventures Limited and Narendra Investments (Delhi) Limited. It is led by directors including Bhavesh Dhirajlal Tanna and Kajal Dhanpatraj Kothari.
Last AGM: 05 September 2025. Financial statements filed for year ended 31 March 2025. Office: 604 Centrum Opp. Tmc Office Near Satkar Grande Hotel Wagle Estate, Thane, Maharashtra, India – 400604.
As per the financials filed for FY 2025, the company reported a revenue of ₹38.38 Cr, a growth of 37% compared to the previous year.
The company is associated with 2 brands - Eiko Lifesciences Limited, Narendra Investments. As per MCA filings, the company has open charges of ₹10 Cr and satisfied charges of ₹8 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website eikolifesciences.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered Address604 Centrum Opp. Tmc Office Near Satkar Grande Hotel Wagle Estate, Thane, Maharashtra, India – 400604
-
IndustryChemicals and Materials, Specialty Chemicals
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Eiko Lifesciences Limited
Eiko Lifesciences Limited has undergone 4 name changes throughout its history. The current legal name is Eiko Lifesciences Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Eiko Lifesciences Limited | Current |
| Ornate Ventures Limited | Previous |
| Narendra Investments (Delhi) Limited | Previous |
| Odin Ventures Limited | Previous |
CIN History of Eiko Lifesciences Limited
Eiko Lifesciences Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L65993MH1977PLC258134, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L65993MH1977PLC258134 | Current |
| L65993DL1977PLC008460 | Previous |
| U65993DL1977PLC008460 | Previous |
Associated Brands with Eiko Lifesciences Limited
Eiko Lifesciences Limited operates two associated brands: Eiko LifeSciences Limited and Narendra Investments. These brands represent Eiko Lifesciences Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Functions as an investment management firm handling diversified funds and portfolios. | narendrainvestment.com | |
| Manufacturing and exporting of speciality chemicals and pharma intermediates in India. | eikolifesciences.com |
Competitors & Alternatives of Eiko Lifesciences Limited
Brands and companies operating in the same space as Eiko Lifesciences Limited include Fidelity Investments, UTI Mutual Fund, Goldman Sachs and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Fidelity Investments
|
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms | Boston, United States, United States | 1946 |
UTI Mutual Fund
|
Mutual funds, portfolio management, and retirement planning services are offered. | Mumbai, India, India | 2001 |
Goldman Sachs
|
Investment banking services are delivered across multiple financial sectors. | New York, United States, United States | 1869 |
S&P Global
|
Platform offering business intelligence solutions that combine data and actionable analytics for clients | New York, United States, United States | 1917 |
Sundaram Finance
|
Provider of consumer & SME loans and equipment & vehicle leasing services | Chennai, India, India | 1954 |
Bank of America
|
Commercial banking and asset management services are offered worldwide. | Charlotte, United States, United States | 1904 |
State Street
|
Financial services are provided to asset managers worldwide. | Boston, United States, United States | - |
FIS
|
Software suites for banks and financial institutions are provided. | Jacksonville, United States, United States | 1968 |
Avendus
|
Corporate advisory and investment services are provided to clients. | Mumbai, India, India | 1999 |
360 One
|
Asset and wealth management software is provided for businesses. | Mumbai, India, India | 2008 |
Business Activity of Eiko Lifesciences Limited
Eiko Lifesciences Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Eiko Lifesciences Limited
Eiko Lifesciences Limited is audited by PSV Jain And Associates (ICAI peer reviewed, certificate valid till 2029-04-30) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| PSV Jain And Associates (ICAI peer reviewed, certificate valid till 2029-04-30) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Eiko Lifesciences Limited
Eiko Lifesciences Limited is currently managed by 8 directors, with 28 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Bhavesh Dhirajlal Tanna
Also directs:
Eiko Lifesciences Limited, Sarthak Corporate Advisors Llp
|
Director | 26 Aug 2013 | 12 Years 10 Months | Current |
|
Kajal Dhanpatraj Kothari
Also directs:
Eiko Lifesciences Limited, Fresh Box Media Private Limited
|
Director | 09 Sep 2020 | 5 Years 10 Months | Current |
|
Laxmikant Ramprasad Kabra
Also directs:
Dhanraj Highrise Llp, Laxmikant Kabra & Co Llp, Eiko Scientific Solutions Llp and 2 more
|
Director | 26 Aug 2013 | 12 Years 10 Months | Current |
|
Sumukh Prabhakar Vartak
Also directs:
Eiko Lifesciences Limited, Uv Wellness Private Limited
|
Whole-Time Director | 29 Jul 2025 | 0 Years 11 Months | Current |
| Rajkumar Govindas Baheti | Director | 10 Feb 2021 | 5 Years 5 Months | Current |
|
Hasti Arjav Doshi
Also directs:
Eiko Lifesciences Limited
|
Director | 03 Sep 2024 | 1 Years 10 Months | Current |
Financials of Eiko Lifesciences Limited FY 2026 filings available
Eiko Lifesciences Limited reported revenue of ₹52.71 Cr (up 39.94% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 | FY 2020 |
|---|---|---|---|
| Revenue from Operations | ₹52.71 Cr | ₹37.66 Cr | ₹10.35 Cr |
| Other Income | ₹97.28 Lakh | ₹71.61 Lakh | ₹5.85 Lakh |
| Total Income | ₹53.68 Cr | ₹38.38 Cr | ₹10.41 Cr |
| Cost of Materials Consumed | ₹41.28 Cr | ₹35.04 Cr | ₹7.85 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹1.31 Lakh | -₹2.38 Cr | -₹23.79 Lakh |
| Employee Benefit Expense | ₹66.63 Lakh | ₹36.66 Lakh | ₹2.64 Cr |
| Finance Costs | ₹32.97 Lakh | ₹15.87 Lakh | ₹24.23 Lakh |
| Depreciation & Amortisation | ₹1.02 Cr | ₹73.72 Lakh | ₹19.29 Lakh |
| Other Expenses | ₹3.31 Cr | ₹1.88 Cr | ₹4.66 Cr |
| Total Expenses | ₹46.61 Cr | ₹35.8 Cr | ₹15.34 Cr |
| Profit Before Exceptional Items & Tax | ₹7.06 Cr | ₹2.58 Cr | -₹4.93 Cr |
| Exceptional Items | ₹0 | ₹34.12 Lakh | ₹0 |
| Profit Before Tax | ₹7.06 Cr | ₹2.92 Cr | -₹4.93 Cr |
| Total Tax Expense | ₹1.79 Cr | ₹74.63 Lakh | -₹1.31 Cr |
| Net Profit | ₹5.32 Cr | ₹2.32 Cr | -₹3.62 Cr |
| attributable to Owners | ₹4.5 Cr | ₹2.11 Cr | -₹1.91 Cr |
| attributable to NCI | ₹82.84 Lakh | ₹21.29 Lakh | -₹1.71 Cr |
| Other Comprehensive Income | ₹0 | ₹0 | -₹7.29 Lakh |
| Total Comprehensive Income | ₹5.32 Cr | ₹2.32 Cr | -₹3.69 Cr |
| EBITDA (computed) | ₹8.41 Cr | ₹3.48 Cr | -₹4.5 Cr |
| Basic EPS | ₹3.26 | ₹1.62 | ₹-4.99 |
| Diluted EPS | ₹3.19 | ₹1.62 | ₹-4.99 |
| Metrics | FY 2026 | FY 2025 | FY 2020 |
|---|---|---|---|
| Total Assets | ₹89.37 Cr | ₹66.1 Cr | ₹12.05 Cr |
| Non-current Assets | ₹41.96 Cr | ₹33.22 Cr | ₹7.03 Cr |
| Current Assets | ₹47.41 Cr | ₹32.88 Cr | ₹5.03 Cr |
| Property, Plant & Equipment | ₹22.1 Cr | ₹23.12 Cr | ₹1.47 Cr |
| Inventories | ₹3.97 Cr | ₹5.77 Cr | ₹3.21 Cr |
| Trade Receivables | ₹20.22 Cr | ₹10.79 Cr | ₹1.18 Cr |
| Cash & Equivalents | ₹13.61 Cr | ₹11.78 Cr | ₹2.43 Lakh |
| Equity (Net Worth) | ₹69.82 Cr | ₹57.01 Cr | ₹1.11 Cr |
| Equity Share Capital | ₹14.35 Cr | ₹13.76 Cr | ₹3.82 Cr |
| Borrowings (Non-current) | ₹3.06 Cr | ₹2.01 Cr | ₹1.61 Cr |
| Borrowings (Current) | ₹1.67 Cr | ₹75.51 Lakh | ₹0 |
| Total Debt (computed) | ₹4.73 Cr | ₹2.76 Cr | ₹1.61 Cr |
| Current Liabilities | ₹15.38 Cr | ₹6.27 Cr | ₹9.33 Cr |
| Total Liabilities | ₹19.54 Cr | ₹9.09 Cr | ₹10.94 Cr |
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Operating Cash Flow | ₹2.28 Cr | ₹2.92 Cr |
| Investing Cash Flow | -₹8.66 Cr | -₹11.44 Cr |
| Financing Cash Flow | ₹8.21 Cr | ₹6.96 Cr |
| Capital Expenditure | ₹0 | ₹10.29 Cr |
| Free Cash Flow (computed) | ₹2.28 Cr | -₹7.37 Cr |
| Dividends Paid | ₹0 | ₹0 |
| Net Change in Cash | ₹1.83 Cr | -₹1.57 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹18.34 Cr | ₹11.98 Cr | ₹11.67 Cr | ₹10.71 Cr | ₹11.27 Cr | ₹7.49 Cr | ₹8.16 Cr | ₹10.75 Cr |
| Other Income | ₹12.95 Lakh | ₹31.71 Lakh | ₹26.1 Lakh | ₹26.52 Lakh | ₹22.98 Lakh | ₹9.35 Lakh | ₹13.07 Lakh | ₹26.23 Lakh |
| Total Income | ₹18.47 Cr | ₹12.3 Cr | ₹11.93 Cr | ₹10.98 Cr | ₹11.5 Cr | ₹7.58 Cr | ₹8.29 Cr | ₹11.01 Cr |
| Cost of Materials Consumed | ₹16.66 Cr | ₹9.01 Cr | ₹10.16 Cr | ₹5.46 Cr | ₹12 Cr | ₹6.27 Cr | ₹6.86 Cr | ₹9.92 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹1.59 Cr | ₹20.51 Lakh | -₹1.44 Cr | ₹2.84 Cr | -₹2.88 Cr | ₹15.89 Lakh | ₹34.1 Lakh | -₹16,000 |
| Employee Benefit Expense | ₹20.77 Lakh | ₹19.57 Lakh | ₹13.74 Lakh | ₹12.56 Lakh | ₹10.63 Lakh | ₹14.01 Lakh | ₹6.7 Lakh | ₹13.05 Lakh |
| Finance Costs | ₹11.51 Lakh | ₹6.68 Lakh | ₹9.97 Lakh | ₹4.82 Lakh | ₹6.71 Lakh | ₹2.7 Lakh | ₹3.58 Lakh | ₹16.53 Lakh |
| Depreciation & Amortisation | ₹25.24 Lakh | ₹25.5 Lakh | ₹25.5 Lakh | ₹25.37 Lakh | ₹25.02 Lakh | ₹15.88 Lakh | ₹16.31 Lakh | ₹2.88 Lakh |
| Other Expenses | ₹78.4 Lakh | ₹69.77 Lakh | ₹1.05 Cr | ₹77.33 Lakh | ₹73.49 Lakh | ₹28.78 Lakh | ₹46.88 Lakh | ₹30.67 Lakh |
| Total Expenses | ₹16.42 Cr | ₹10.43 Cr | ₹10.26 Cr | ₹9.5 Cr | ₹10.27 Cr | ₹7.04 Cr | ₹7.93 Cr | ₹10.55 Cr |
| Profit Before Exceptional Items & Tax | ₹2.05 Cr | ₹1.87 Cr | ₹1.67 Cr | ₹1.47 Cr | ₹1.23 Cr | ₹54.11 Lakh | ₹35.25 Lakh | ₹46.14 Lakh |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹34.12 Lakh | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹2.05 Cr | ₹1.87 Cr | ₹1.67 Cr | ₹1.47 Cr | ₹1.57 Cr | ₹54.11 Lakh | ₹35.25 Lakh | ₹46.14 Lakh |
| Total Tax Expense | ₹52.16 Lakh | ₹47.67 Lakh | ₹42.7 Lakh | ₹36.77 Lakh | ₹39.33 Lakh | ₹14.38 Lakh | ₹9.47 Lakh | ₹11.45 Lakh |
| Net Profit | ₹1.5 Cr | ₹1.43 Cr | ₹1.28 Cr | ₹1.12 Cr | ₹1.24 Cr | ₹42.21 Lakh | ₹28.15 Lakh | ₹37.14 Lakh |
| attributable to Owners | ₹1.3 Cr | ₹1.21 Cr | ₹1.08 Cr | ₹91.42 Lakh | ₹1.05 Cr | - | - | - |
| attributable to NCI | ₹19.7 Lakh | ₹21.91 Lakh | ₹20.91 Lakh | ₹20.31 Lakh | ₹19.84 Lakh | - | - | - |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | ₹1.5 Cr | ₹1.43 Cr | ₹1.28 Cr | ₹1.12 Cr | ₹1.24 Cr | ₹42.21 Lakh | ₹28.15 Lakh | ₹37.14 Lakh |
| EBITDA (computed) | ₹2.42 Cr | ₹2.19 Cr | ₹2.03 Cr | ₹1.78 Cr | ₹1.54 Cr | ₹72.69 Lakh | ₹55.14 Lakh | ₹65.55 Lakh |
| Basic EPS | ₹0.93 | ₹0.88 | ₹0.78 | ₹0.66 | ₹0.80 | ₹0.32 | ₹0.22 | ₹0.29 |
| Diluted EPS | ₹0.86 | ₹0.88 | ₹0.78 | ₹0.66 | ₹0.80 | ₹0.32 | ₹0.22 | ₹0.29 |
| Segment · Q4 FY26 (latest quarter) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Speciality Chemicals & Pharma Intermediates | ₹16.88 Cr | ₹1.25 Cr | ₹43.37 Cr | ₹15.46 Cr |
| Logistics Services | ₹1.46 Cr | ₹28.93 Lakh | ₹17.16 Cr | ₹4.08 Cr |
| Segment · FY 2026 (annual) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Speciality Chemicals & Pharma Intermediates | ₹46.03 Cr | ₹3.23 Cr | - | - |
| Logistics Services | ₹6.68 Cr | ₹1.21 Cr | - | - |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹42.13 Cr | ₹32.49 Cr | ₹27.93 Cr | ₹18.32 Cr | ₹25.41 Cr | ₹11.99 Cr | ₹35.5 Lakh | ₹36.54 Lakh |
| Other Income | ₹2.13 Cr | ₹1.02 Cr | ₹17.61 Lakh | ₹85.48 Lakh | ₹67.33 Lakh | ₹46.03 Lakh | ₹7.46 Lakh | ₹2.09 Lakh |
| Total Income | ₹44.26 Cr | ₹33.52 Cr | ₹28.11 Cr | ₹19.18 Cr | ₹26.09 Cr | ₹12.45 Cr | ₹42.96 Lakh | ₹38.63 Lakh |
| Cost of Materials Consumed | ₹37.28 Cr | ₹29.83 Cr | ₹27.2 Cr | ₹13.66 Cr | ₹25.05 Cr | ₹10.61 Cr | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹1.31 Lakh | -₹62.22 Lakh | -₹1.79 Cr | ₹2.43 Cr | -₹2.47 Cr | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹29.01 Lakh | ₹28.29 Lakh | ₹22.07 Lakh | ₹28.71 Lakh | ₹27.7 Lakh | ₹11.83 Lakh | ₹7.02 Lakh | ₹2.46 Lakh |
| Finance Costs | ₹16.29 Lakh | ₹12.7 Lakh | ₹14.21 Lakh | ₹15.03 Lakh | ₹46.42 Lakh | ₹8.78 Lakh | ₹6.83 Lakh | ₹3.17 Lakh |
| Depreciation & Amortisation | ₹59.02 Lakh | ₹62.94 Lakh | ₹66.25 Lakh | ₹63.28 Lakh | ₹56.24 Lakh | ₹6.16 Lakh | ₹6.16 Lakh | ₹6.16 Lakh |
| Other Expenses | ₹1.2 Cr | ₹1.29 Cr | ₹68.17 Lakh | ₹98.64 Lakh | ₹1.26 Cr | ₹73.85 Lakh | ₹9.94 Lakh | ₹16.9 Lakh |
| Total Expenses | ₹39.54 Cr | ₹31.54 Cr | ₹27.12 Cr | ₹18.15 Cr | ₹25.14 Cr | ₹11.62 Cr | ₹29.96 Lakh | ₹28.69 Lakh |
| Profit Before Exceptional Items & Tax | ₹4.71 Cr | ₹1.98 Cr | ₹98.42 Lakh | ₹1.03 Cr | ₹94.2 Lakh | ₹83.27 Lakh | ₹13.01 Lakh | ₹9.94 Lakh |
| Exceptional Items | ₹0 | ₹34.12 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹4.71 Cr | ₹2.32 Cr | ₹98.42 Lakh | ₹1.03 Cr | ₹94.2 Lakh | ₹83.27 Lakh | ₹13.01 Lakh | ₹9.94 Lakh |
| Total Tax Expense | ₹1.13 Cr | ₹57.74 Lakh | ₹23.24 Lakh | ₹25.74 Lakh | ₹23.63 Lakh | ₹21.84 Lakh | ₹22,800 | ₹2.7 Lakh |
| Net Profit | ₹3.58 Cr | ₹1.74 Cr | ₹75.15 Lakh | ₹76.88 Lakh | ₹70.57 Lakh | ₹61.43 Lakh | ₹12.78 Lakh | ₹7.24 Lakh |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹2.4 Lakh | -₹1.64 Lakh | ₹8.97 Lakh | -₹7.29 Lakh | -₹19.34 Lakh |
| Total Comprehensive Income | ₹3.58 Cr | ₹1.74 Cr | ₹75.15 Lakh | ₹79.28 Lakh | ₹68.94 Lakh | ₹70.4 Lakh | ₹5.49 Lakh | -₹12.1 Lakh |
| EBITDA (computed) | ₹5.47 Cr | ₹2.73 Cr | ₹1.79 Cr | ₹1.81 Cr | ₹1.97 Cr | ₹98.21 Lakh | ₹26 Lakh | ₹19.27 Lakh |
| Basic EPS | ₹2.60 | ₹1.34 | ₹0.73 | ₹0.92 | ₹0.90 | ₹1.61 | ₹0.33 | ₹0.02 |
| Diluted EPS | ₹2.54 | ₹1.34 | ₹0.73 | ₹0.92 | ₹0.90 | ₹1.61 | ₹0.33 | ₹0.02 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹82.79 Cr | ₹60.37 Cr | ₹52.74 Cr | ₹31.04 Cr | ₹34.89 Cr | ₹16.61 Cr | ₹5.76 Cr | ₹5.76 Cr |
| Non-current Assets | ₹44.34 Cr | ₹31.96 Cr | ₹21.81 Cr | ₹21.74 Cr | ₹22.46 Cr | ₹5.91 Cr | ₹5.66 Cr | ₹5.06 Cr |
| Current Assets | ₹38.45 Cr | ₹28.42 Cr | ₹30.93 Cr | ₹9.3 Cr | ₹12.44 Cr | ₹10.7 Cr | ₹10.03 Lakh | ₹70.87 Lakh |
| Property, Plant & Equipment | ₹13.67 Cr | ₹14.26 Cr | ₹13.57 Cr | ₹13.88 Cr | ₹14.29 Cr | ₹24.75 Lakh | ₹30.91 Lakh | ₹37.07 Lakh |
| Inventories | ₹3.97 Cr | ₹4.02 Cr | ₹3.39 Cr | ₹90.76 Lakh | ₹5.46 Cr | ₹6.35 Lakh | ₹0 | ₹0 |
| Trade Receivables | ₹18.89 Cr | ₹10.14 Cr | ₹13.13 Cr | ₹7.11 Cr | ₹4.56 Cr | ₹3.41 Cr | ₹0 | ₹8.48 Lakh |
| Cash & Equivalents | ₹13.55 Cr | ₹11.51 Cr | ₹13.35 Cr | ₹61.24 Lakh | ₹21.73 Lakh | ₹7,900 | ₹1.77 Lakh | ₹2.51 Lakh |
| Equity (Net Worth) | ₹67.5 Cr | ₹56.42 Cr | ₹50.68 Cr | ₹29.42 Cr | ₹28.63 Cr | ₹12.53 Cr | ₹5.48 Cr | ₹5.43 Cr |
| Equity Share Capital | ₹14.35 Cr | ₹13.76 Cr | ₹12.87 Cr | ₹8.32 Cr | ₹8.32 Cr | ₹3.82 Cr | ₹3.82 Cr | ₹3.82 Cr |
| Borrowings (Non-current) | ₹0 | ₹99.89 Lakh | ₹0 | ₹0 | ₹5.36 Lakh | ₹1.76 Cr | ₹19.6 Lakh | ₹25.79 Lakh |
| Borrowings (Current) | ₹1.67 Cr | ₹75.51 Lakh | ₹0 | ₹0 | ₹4.5 Cr | ₹0 | ₹0 | ₹5.65 Lakh |
| Total Debt (computed) | ₹1.67 Cr | ₹1.75 Cr | ₹0 | ₹0 | ₹4.55 Cr | ₹1.76 Cr | ₹19.6 Lakh | ₹31.43 Lakh |
| Current Liabilities | ₹14.53 Cr | ₹2.27 Cr | ₹1.5 Cr | ₹1.2 Cr | ₹6.01 Cr | ₹2.33 Cr | ₹8.42 Lakh | ₹7.93 Lakh |
| Total Liabilities | ₹15.29 Cr | ₹3.95 Cr | ₹2.06 Cr | ₹1.62 Cr | ₹6.26 Cr | ₹4.09 Cr | ₹28.02 Lakh | ₹33.72 Lakh |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹6.92 Cr | ₹2.05 Cr | -₹7.08 Cr | ₹4.22 Cr | -₹7.73 Cr |
| Investing Cash Flow | -₹11.21 Cr | -₹9.85 Cr | -₹54.89 Lakh | ₹87.47 Lakh | ₹59.23 Lakh |
| Financing Cash Flow | ₹6.33 Cr | ₹5.97 Cr | ₹20.36 Cr | -₹4.7 Cr | ₹3.28 Cr |
| Capital Expenditure | ₹0 | ₹1.33 Cr | ₹34.65 Lakh | ₹22.47 Lakh | ₹15.46 Lakh |
| Free Cash Flow (computed) | ₹6.92 Cr | ₹71.95 Lakh | -₹7.43 Cr | ₹4 Cr | -₹7.88 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | ₹2.04 Cr | -₹1.83 Cr | ₹12.73 Cr | ₹39.5 Lakh | -₹3.85 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹15.9 Cr | ₹9.57 Cr | ₹9.2 Cr | ₹7.45 Cr | ₹7.09 Cr | ₹6.91 Cr | ₹7.74 Cr | ₹10.75 Cr |
| Other Income | ₹45.44 Lakh | ₹55.65 Lakh | ₹56.47 Lakh | ₹55.37 Lakh | ₹52.64 Lakh | ₹10.47 Lakh | ₹13.07 Lakh | ₹26.23 Lakh |
| Total Income | ₹16.36 Cr | ₹10.13 Cr | ₹9.76 Cr | ₹8.01 Cr | ₹7.62 Cr | ₹7.02 Cr | ₹7.87 Cr | ₹11.01 Cr |
| Cost of Materials Consumed | ₹15.87 Cr | ₹8.18 Cr | ₹8.63 Cr | ₹4.6 Cr | ₹7.35 Cr | ₹5.94 Cr | ₹6.61 Cr | ₹9.92 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹1.59 Cr | ₹20.51 Lakh | -₹56.23 Lakh | ₹1.96 Cr | -₹1.12 Cr | ₹15.89 Lakh | ₹34.1 Lakh | -₹16,000 |
| Employee Benefit Expense | ₹7.17 Lakh | ₹8.96 Lakh | ₹7.03 Lakh | ₹5.85 Lakh | ₹6.4 Lakh | ₹10.66 Lakh | ₹5.91 Lakh | ₹13.05 Lakh |
| Finance Costs | ₹3.82 Lakh | ₹3.68 Lakh | ₹6.97 Lakh | ₹1.82 Lakh | ₹3.82 Lakh | ₹2.42 Lakh | ₹3.58 Lakh | ₹2.88 Lakh |
| Depreciation & Amortisation | ₹14.74 Lakh | ₹14.76 Lakh | ₹14.76 Lakh | ₹14.75 Lakh | ₹14.74 Lakh | ₹15.37 Lakh | ₹16.31 Lakh | ₹16.53 Lakh |
| Other Expenses | ₹32.81 Lakh | ₹22.32 Lakh | ₹34.18 Lakh | ₹30.98 Lakh | ₹28.44 Lakh | ₹24.84 Lakh | ₹37.71 Lakh | ₹30.67 Lakh |
| Total Expenses | ₹14.86 Cr | ₹8.89 Cr | ₹8.69 Cr | ₹7.1 Cr | ₹6.76 Cr | ₹6.63 Cr | ₹7.59 Cr | ₹10.55 Cr |
| Profit Before Exceptional Items & Tax | ₹1.49 Cr | ₹1.24 Cr | ₹1.07 Cr | ₹90.77 Lakh | ₹85.46 Lakh | ₹38.07 Lakh | ₹28.02 Lakh | ₹46.14 Lakh |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹34.12 Lakh | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹1.49 Cr | ₹1.24 Cr | ₹1.07 Cr | ₹90.77 Lakh | ₹1.2 Cr | ₹38.07 Lakh | ₹28.02 Lakh | ₹46.14 Lakh |
| Total Tax Expense | ₹36.94 Lakh | ₹29.65 Lakh | ₹25.05 Lakh | ₹21.55 Lakh | ₹29.48 Lakh | ₹9.58 Lakh | ₹7.22 Lakh | ₹11.45 Lakh |
| Net Profit | ₹1.12 Cr | ₹94.75 Lakh | ₹81.75 Lakh | ₹69.22 Lakh | ₹90.1 Lakh | ₹28.49 Lakh | ₹20.8 Lakh | ₹34.69 Lakh |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | ₹1.12 Cr | ₹94.75 Lakh | ₹81.75 Lakh | ₹69.22 Lakh | ₹90.1 Lakh | ₹28.49 Lakh | ₹20.8 Lakh | ₹34.69 Lakh |
| EBITDA (computed) | ₹1.68 Cr | ₹1.43 Cr | ₹1.29 Cr | ₹1.07 Cr | ₹1.04 Cr | ₹55.86 Lakh | ₹47.91 Lakh | ₹65.55 Lakh |
| Basic EPS | ₹0.80 | ₹0.69 | ₹0.60 | ₹0.50 | ₹0.69 | ₹0.24 | ₹0.16 | ₹0.27 |
| Diluted EPS | ₹0.74 | ₹0.69 | ₹0.60 | ₹0.50 | ₹0.69 | ₹0.24 | ₹0.16 | ₹0.27 |
Shareholding Pattern of Eiko Lifesciences Limited
As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, promoters hold 39.91%, retail and other public shareholders hold 60.09% of Eiko Lifesciences Limited. The company had 2,969 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 39.91% | 37.17% | 37.17% | 36.74% | 36.23% | 31.27% |
| Public | 60.09% | 62.83% | 62.83% | 63.26% | 63.77% | 68.73% |
| Mar 2026 | Mar 2025 | Mar 2024 | |
|---|---|---|---|
| Promoters | 39.91% | 36.23% | 24.23% |
| Public | 60.09% | 63.77% | 75.77% |
| Promoter change (YoY, %pts) | +3.68 | +12.00 | - |
Charges & Borrowings of Eiko Lifesciences Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Sep 2025 | Bank of India | ₹10 Cr | Open |
| 30 Nov 2024 | Others | ₹1 Cr | Satisfied |
| 13 May 2021 | Others | ₹7 Cr | Satisfied |
Total charge records: 3 View all charges
Employees and EPFO Compliance at Eiko Lifesciences Limited
View historical data on people associated with Eiko Lifesciences Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Eiko Lifesciences Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Eiko Lifesciences Limited
GSTIN & GST Filing Data of Eiko Lifesciences Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Eiko Lifesciences Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Eiko Lifesciences Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Eiko Lifesciences Limited
MSME Payment Delays by Eiko Lifesciences Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Eiko Lifesciences Limited
Subsidiaries & Group Companies of Eiko Lifesciences Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Eiko Lifesciences Limited with ownership details.
MCA Filings & Documents of Eiko Lifesciences Limited
MCA Filings & Documents of Eiko Lifesciences Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Eiko Lifesciences Limited
Frequently Asked Questions about Eiko Lifesciences Limited
Eiko Lifesciences Limited is an active public limited company in the chemicals and materials sector based in Thane, Maharashtra, India. It was incorporated on 07 January 1977 (49+ years old) and is registered under CIN L65993MH1977PLC258134. Listed on BSE: 540204.
Eiko Lifesciences Limited reported revenue of ₹38.38 Cr for FY 2025 (up 37.00% YoY).
The current directors of Eiko Lifesciences Limited are:
- Bhavesh Dhirajlal Tanna
- Kajal Dhanpatraj Kothari
- Chintan Bharatbhai Doshi
- Laxmikant Ramprasad Kabra
- Jaid Ismail Kojar
- Sumukh Prabhakar Vartak
- Rajkumar Govindas Baheti
- Hasti Arjav Doshi
The primary industry of Eiko Lifesciences Limited is chemicals and materials. The company specifically operates in specialty chemicals. The company is currently active in this sector.
Yes. Eiko Lifesciences Limited is listed on BSE with code 540204.
Eiko Lifesciences Limited can be reached at the registered office: 604 Centrum Opp. Tmc Office Near Satkar Grande Hotel Wagle Estate, Thane, Maharashtra, India – 400604, or through the website eikolifesciences.com.